Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20
You may also be interested in...
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent
Medtronic R&D Spending Shifts To Neuromodulation, Diabetes
Medtronic is allocating an increasing share of R&D resources to its high-growth neuromodulation and diabetes care segments, at the expense of its larger but slower-growing cardiac rhythm disease management and cardiovascular care businesses